A modified release composition comprising 5-[4-[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione

PK139970AUndetermined Publication Date: 2009-02-20SMITHKLINE BEECHAM CORP
0 Cites 0 Cited by

Patent Information

Application Number
PK199900959
Authority / Receiving Office
PK · PK
Patent Type
Applications
Current Assignee / Owner
Publication Date
2009-02-20
Patent Text Reader

Abstract

A sustained release pharmaceutical composition comprising 2 to 12 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl) amino) ethoxy]benzyl]thiazoline-2, 4-dione or solvate thereof and a pharmaceutically acceptable carrier therefor, which dosage from provides a plasma concentration of 5-[4-[2-(N-methyl-N-(2-pyridyl) amino) ethoxy] benzyl]thiazoline-2, 4-dione of at least 50 ng / ml over a period of up to 24 hours.
Need to check novelty before this filing date? Find Prior Art